Avinger Inc. (NASDAQ:AVGR) traded down 5.3% during trading on Monday . The company traded as low as $4.61 and last traded at $4.68, with a volume of 146,713 shares trading hands. The stock had previously closed at $4.94.

A number of equities research analysts have commented on the company. Zacks Investment Research upgraded Avinger from a “sell” rating to a “hold” rating in a research report on Tuesday, May 3rd. Canaccord Genuity reaffirmed a “buy” rating on shares of Avinger in a research note on Tuesday, July 12th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Avinger in a research note on Friday, July 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $18.75.

The firm’s 50 day moving average price is $9.04 and its 200 day moving average price is $11.58. The stock’s market capitalization is $56.23 million.

Avinger (NASDAQ:AVGR) last released its quarterly earnings results on Monday, August 1st. The medical device company reported ($1.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.09. The firm earned $4.70 million during the quarter, compared to analyst estimates of $3.05 million. Equities analysts predict that Avinger Inc. will post ($4.26) EPS for the current fiscal year.

In related news, insider Himanshu Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $13.40, for a total value of $134,000.00. Following the sale, the insider now owns 87,220 shares in the company, valued at approximately $1,168,748. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Donald A. Lucas sold 9,309 shares of the company’s stock in a transaction that occurred on Friday, May 6th. The stock was sold at an average price of $12.58, for a total value of $117,107.22. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Avinger stock. Paradigm Capital Management Inc. NY increased its position in shares of Avinger Inc. (NASDAQ:AVGR) by 41.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 367,056 shares of the medical device company’s stock after buying an additional 108,222 shares during the period. Paradigm Capital Management Inc. NY owned approximately 2.91% of Avinger worth $8,336,000 as of its most recent filing with the SEC.

Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses to introduce products based on its lumivascular platform, which is an intravascular image-guided system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.